Clinical Trial Update: Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy [Phase 2]

View source ↗

Summary

Phase II trial of afatinib (BIBW 2992) for HER2-positive metastatic breast cancer after trastuzumab failure has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gilotrif (afatinib) (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-12-23